SCHEMBL24718692

SCHEMBL24718692

COC(=O)c1c(F)cc(Br)c(F)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
TSHR P16473 2/20 0.40
LMNA P02545 2/20 0.40
CYP3A4 P08684 2/20 0.39
ACHE P22303 1/20 0.39
NOTUM Q6P988 2/20 0.37
MAPT P10636 2/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ATM Q13315 1/20 0.37
POLB P06746 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30798376 1.00 SOS1 (0.40) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL7508746 0.88 SOS1 (0.41) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL28642417 0.86 MAPT (0.42) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL31024678 0.85 LMNA (0.42) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL18985227 0.83 LMNA (0.41) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL30867539 0.83 LMNA (0.41) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL24717415 0.83 TPMT (0.41) NPSR1TSHRLMNACYP3A4ACHE
SCHEMBL22208960 0.83 HDAC1 (0.41) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL24649335 0.81 SOS1 (0.39) SOS1NPSR1TSHRLMNACYP3A4
SCHEMBL30427242 0.81 SOS1 (0.39) SOS1NPSR1TSHRLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117279910-A Modulators of BCL6 proteolysis and related methods of use 阿尔维纳斯运营股份有限公司 2023-12-22 CN disclosed
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220395576-A1 MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE BCL6, BCL6B, BCL3 SOS1 1077/4885NPSR1 4484/4885TSHR 3100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.